Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,598.00
Bid: 1,601.00
Ask: 1,602.00
Change: -168.50 (-9.54%)
Spread: 1.00 (0.062%)
Open: 1,616.50
High: 1,637.50
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Astrazeneca leads FTSE higher on bid speculation

Thu, 21st Aug 2014 17:42

- Healthcare stocks lift FTSE- German PMI data drives sentiment- Investors look ahead to Draghi speech- UK retail sales disappointtechMARK 2,819.77 +0.82%FTSE 100 6,777.66 +0.33%FTSE 250 15,838.57 +0.57%London's blue chips ended Thursday's session on a positive note, led by Astrazeneca. Increased speculation regarding ECB action, on the heels of weaker than forecast readings on the Eurozone economy, were offset by a weak report on UK retail sales. After making gains both early and late on, the FTSE 100 ultimately closed 22 points higher at 6,778. July saw UK retail sales register their slowest annual gain since November, with volumes surprising with a slowdown to just a 0.1% rate of gain, compared to an advance of 0.2% in June. Expectations had been for a rise of 0.4%. Investors were also surprised to see that food sales declined, the first time on record that this has happened. The Office for National Statistics also released figures showing that while UK public finances improved last month borrowing still remained above the government's target.Across the Channel, Markit's 'flash' composite Purchasing Managers' Index (PMI), which tracks growth in the manufacturing and service sectors that make up more than two-thirds of the economy, fell to 54.9 in August from 55.7. However, it nonetheless remained well above the crucial 50 mark that separates growth from contraction.On the upside, Germany's private sector grew for a 16th month running in August, suggesting Europe's largest economy could expand robustly in the third quarter after it suffered a surprise contraction in the second.However, following those figures Barclays Research pointed out that it sees "material downside risks" to its forecast for the Eurozone's GDP to expand at 0.3% quarter-on-quarter clip in the third quarter. Meanwhile, the Jackson Hole Symposium of central bankers is due to kick off later Stateside with comments from policymakers around the world likely to be closely watched.Bid speculation sends Astrazeneca racing aheadHealthcare stocks gained strongly amid speculation Pfizer may make another bid for Astrazeneca. Smith & Nephew and GlaxoSmithKline also rose strongly. Financial stocks also made decent gains, with Hargreaves Lansdown, Standard Life, Old Mutual and Aviva all higher. Mining stocks led to the downside after metals consumer China disappointed with its manufacturing data and metals prices fell. Fresnillo, Randgold Resources, Anglo American, Rio Tinto and BHP Billiton all fell into the red. BHP was still under pressure in the aftermath of Tuesday's underwhelming plans for a demerger. Chief financial officer Graham Kerr, who is due to be the head of the spin-off company, has been cited as saying that the lack of a share buyback - which many investors had been expecting - was a "sore point", while plans to give shareholders stock in the new firm may have "irritated" some who are not mandated to hold investments in Australia. Oil stock Tullow Oil was also in the red. On the second tier, metal miner Kazakhmys hailed progress with a shake-up designed to focus it on the lucrative copper market, but said 2014 gold production was likely to fall short of hopes, pushing the stock into the red. Investec knocked Ophir Energy lower after it reduced its rating to 'hold' from 'buy' and lowered its target price to 250p from 315p.FTSE 100 - RisersAstraZeneca (AZN) 4,411.50p +2.95%Schroders (SDR) 2,392.00p +2.66%Hargreaves Lansdown (HL.) 1,133.00p +2.16%CRH (CRH) 1,401.00p +2.04%Barratt Developments (BDEV) 366.20p +1.84%Smith & Nephew (SN.) 1,064.00p +1.62%3i Group (III) 387.60p +1.57%Standard Life (SL.) 376.90p +1.48%Mondi (MNDI) 1,018.00p +1.39%Rolls-Royce Holdings (RR.) 1,037.00p +1.37%FTSE 100 - FallersFresnillo (FRES) 938.00p -3.55%Randgold Resources Ltd. (RRS) 4,904.00p -1.86%Kingfisher (KGF) 306.80p -1.67%Anglo American (AAL) 1,573.50p -1.29%Antofagasta (ANTO) 808.50p -1.28%Royal Mail (RMG) 440.30p -1.21%Petrofac Ltd. (PFC) 1,126.00p -1.14%easyJet (EZJ) 1,324.00p -1.12%Aberdeen Asset Management (ADN) 431.70p -1.10%Rio Tinto (RIO) 3,433.00p -0.72%FTSE 250 - RisersSenior (SNR) 292.40p +3.84%Hikma Pharmaceuticals (HIK) 1,742.00p +2.96%Ocado Group (OCDO) 377.90p +2.89%Phoenix Group Holdings (DI) (PHNX) 735.50p +2.87%RPS Group (RPS) 269.50p +2.86%Cranswick (CWK) 1,349.00p +2.82%International Personal Finance (IPF) 520.00p +2.77%Diploma (DPLM) 686.00p +2.62%Spirent Communications (SPT) 103.50p +2.48%Carillion (CLLN) 337.60p +2.30%FTSE 250 - FallersKazakhmys (KAZ) 291.10p -5.64%Petra Diamonds Ltd.(DI) (PDL) 183.60p -3.72%Ophir Energy (OPHR) 221.40p -3.61%Exova Group (EXO) 220.00p -3.51%Just Retirement Group (JRG) 146.20p -2.60%Thomas Cook Group (TCG) 121.00p -2.42%Electrocomponents (ECM) 239.80p -2.36%Ladbrokes (LAD) 132.30p -2.22%Lonmin (LMI) 212.90p -2.11%African Barrick Gold (ABG) 239.60p -1.80%AB
More News
Today 17:20

European shares kick-off June on a high note in anticipation of ECB rate cut

GSK tumbles as Zantac lawsuits allowed to proceed

*

Read more
Today 17:19

Pharma, energy stocks drag London's FTSE 100; ECB rate cut hopes cap losses

FTSE 100 down 0.2%, FTSE 250 up 0.8%

*

Read more
Today 17:00

LONDON MARKET CLOSE: FTSE 100 down amid shaky start in New York

(Alliance News) - The FTSE 100 in London closed lower on Monday, marking a mixed start to June, with GSK firmly at the bottom of the index.

Read more
Today 14:01

GSK immunotherapy bowel cancer drug works for 100% of patients

(Alliance News) - An immunotherapy drug could spare bowel cancer patients the need for surgery and chemotherapy after results showed it was effective in 100% of cases.

Read more
Today 11:58

LONDON MARKET MIDDAY: FTSE 100 up, while Labour commits to defence

(Alliance News) - Stock prices in London were up at midday, after data from S&P Global signalled a return to growth for the UK manufacturing sector.

Read more
Today 09:08

TOP NEWS: GSK vows to appeal adverse Delaware court ruling on Zantac

(Alliance News) - GSK PLC on Monday said it will appeal a US court ruling that it should face jury trials relating to cases concerning the heartburn drug, Zantac.

Read more
Today 08:37

LONDON MARKET OPEN: Stocks up amid slew of manufacturing PMIs

(Alliance News) - Stock prices in London opened higher on Monday, ahead of local purchasing managers index data, and comparative prints from several other major global economies.

Read more
Today 08:00

LONDON BRIEFING: FTSE 100 seen up; GSK defends ranitidine cancer claim

(Alliance News) - Stocks in London are set to open higher on Monday, ahead of a data-heavy week, kicked off by a slew of manufacturing purchasing managers' index readings.

Read more
Today 07:30

GSK to appeal Delaware ruling on jury trials in Zantac cancer cases

(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
31 May 2024 17:45

US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label

May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
31 May 2024 16:01

US FDA approves Moderna's RSV vaccine, its second marketed product

May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.